AbbVie Inc (ABBV) : Sg Americas Securities scooped up 607,924 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 898,718 shares of AbbVie Inc which is valued at $59,827,657.AbbVie Inc makes up approximately 0.45% of Sg Americas Securities’s portfolio.
Other Hedge Funds, Including , Ghp Investment Advisors reduced its stake in ABBV by selling 33 shares or 0.6% in the most recent quarter. The Hedge Fund company now holds 5,439 shares of ABBV which is valued at $362,074. AbbVie Inc makes up approx 0.07% of Ghp Investment Advisors’s portfolio.Stratford Consulting reduced its stake in ABBV by selling 770 shares or 13.88% in the most recent quarter. The Hedge Fund company now holds 4,778 shares of ABBV which is valued at $316,447. AbbVie Inc makes up approx 0.14% of Stratford Consulting’s portfolio. Baxter Bros Inc sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 8,382 shares of ABBV which is valued $537,789.
AbbVie Inc closed down -0.2 points or -0.30% at $66.34 with 53,09,293 shares getting traded on Monday. Post opening the session at $66.38, the shares hit an intraday low of $65.75 and an intraday high of $66.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.